Evidence map›Paper›PMID 39148543›Full record

ArticleFrontiers in pharmacology2024

Angong Niuhuang Wan ameliorates LPS-induced cerebrovascular edema by inhibiting blood‒brain barrier leakage and promoting the membrane expression of AQP4.

Bo-Tong Liu, Quan Li, Kai Sun, Chun-Shui Pan, Xin-Mei Huo, Ping Huang, Li Yan, Qi-Hua He, Li-Jun Zhong, Yuan Wang and 7 more

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Bo-Tong LiuDepartment of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China.
Quan LiTasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.
Kai SunTasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.
Chun-Shui PanTasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.
Xin-Mei HuoDepartment of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China.
Ping HuangTasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.
Li YanTasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.
Qi-Hua HeState Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China.
Li-Jun ZhongPeking University Medical and Health Analysis Center, Peking University, Beijing, China.
Yuan WangState Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China.
Meng-Lei HuDepartment of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China.
An-Qing LiDepartment of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China.
Ying-Qian JiaoDepartment of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China.
Shuang ZhangDepartment of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China.
Xiao-Yi WangDepartment of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China.
Jian LiuDepartment of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China.
Jing-Yan HanDepartment of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Angong Niuhuang Wan (AGNHW), developed during the Qing dynasty (18th century) for the treatment of consciousness disturbances caused by severe infections, has been used to treat brain edema caused by ischemia‒reperfusion. However, it remains unclear whether AGNHW can ameliorate vascular-origin brain edema caused by lipopolysaccharides (LPS). This study explored the ameliorative effects of AGNHW on LPS-induced cerebrovascular edema in mice, as well as the potential underlying mechanisms. Methods: A cerebrovascular edema model was established in male C57BL/6N mice by two intraperitoneal injections of LPS (15 mg/kg), at 0 and 24 h. AGNHW was administered by gavage at doses of 0.2275 g/kg, 0.455 g/kg, and 0.91 g/kg, 2 h after LPS administration. In control mice, normal saline (NS) or AGNHW (0.455 g/kg) was administered by gavage 2 h after intraperitoneal injection of NS. The survival rate, cerebral water content, cerebral venous FITC-dextran leakage, Evans blue extravasation, and expression of vascular endothelial cadherin (VE-cadherin), zonula occludens-1 (ZO-1), claudin-5, phosphorylated caveolin-1 (CAV-1), and cytomembrane and cytoplasmic aquaporin 1 (AQP1) and aquaporin 4 (AQP4) were evaluated. The cerebral tissue phosphoproteome, blood levels of AGNHW metabolites, and the relationships between these blood metabolites and differentially phosphorylated proteins were analyzed. Results: AGNHW inhibited the LPS-induced decrease in survival rate, increase in cerebral water content, decrease in VE-Cadherin expression and increase in phosphorylated CAV-1 ( Conclusion: AGNHW can ameliorate cerebrovascular edema caused by LPS. This effect is associated with the inhibition of VE-Cadherin reduction and CAV-1 phosphorylation, as well as the upregulation of AQP4 expression on the astrocyte membrane, following LPS injection.

Indexed as

AQP4blood-brain barriercerebrovascular edemaPKC-αVE-cadherin

Identifiers

PMID39148543
PMCPMC11324430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.